Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $11.02 and traded as low as $10.30. Bayer Aktiengesellschaft shares last traded at $10.38, with a volume of 586,457 shares trading hands.

Analyst Upgrades and Downgrades

BAYRY has been the subject of several research reports. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Finally, DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The stock has a market capitalization of $40.79 billion, a P/E ratio of -16.22, a PEG ratio of 3.35 and a beta of 0.59. The firm has a 50-day moving average of $11.02 and a 200 day moving average of $11.40. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $15.73 billion during the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Research analysts anticipate that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.